URO 33 Study: Bone Metastases, SREs and Bone

Bone metastases remain an important clinical challenge in metastatic renal cell carcinoma (mRCC), affecting survival and quality of life and increasing the risk of skeletal-related events (SREs). However, evidence on their prognostic impact and the role of bone-targeting agents (BTAs) remains limited in patients receiving contemporary first-line systemic therapy.

A new subanalysis of the Meet-URO 33 study, published as an Article in Press in Clinical Genitourinary Cancer on August 24, 2026, examined bone metastases, SREs, and BTA use in a large real-world cohort of patients with mRCC receiving first-line treatment.

The original study was titled “Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis).”